1.

Perceived work ability and turnover intentions: a prospective study among Belgian healthcare workers

2.

Perceived work ability and turnover intentions: a prospective study among Belgian healthcare workers

3.

Perceived work ability and turnover intentions: a prospective study among Belgian healthcare workers

4.

Perceived work ability and turnover intentions: a prospective study among Belgian healthcare workers

5.

Perceived work ability and turnover intentions: a prospective study among Belgian healthcare workers

6.

Perceived work ability and turnover intentions: a prospective study among Belgian healthcare workers

7.

Perceived work ability and turnover intentions: a prospective study among Belgian healthcare workers

8.

Perceived work ability and turnover intentions: a prospective study among Belgian healthcare workers

1.

Geographical and temporal differences in the urinary excretion of inorganic arsenic: a Belgian population study.

2.

Geographical and temporal differences in the urinary excretion of inorganic arsenic: a Belgian population study.

3.

Geographical and temporal differences in the urinary excretion of inorganic arsenic: a Belgian population study.

4.

Geographical and temporal differences in the urinary excretion of inorganic arsenic: a Belgian population study.

5.

Geographical and temporal differences in the urinary excretion of inorganic arsenic: a Belgian population study.

6.

Geographical and temporal differences in the urinary excretion of inorganic arsenic: a Belgian population study.

7.

Geographical and temporal differences in the urinary excretion of inorganic arsenic: a Belgian population study.

8.

Geographical and temporal differences in the urinary excretion of inorganic arsenic: a Belgian population study.

1.

Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology

2.

Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology

3.

Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology

4.

Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology

1.

Malocclusion, dental injuries and dental anomalies in the primary dentition of Belgian children.

2.

Malocclusion, dental injuries and dental anomalies in the primary dentition of Belgian children.

3.

Malocclusion, dental injuries and dental anomalies in the primary dentition of Belgian children.

4.

Malocclusion, dental injuries and dental anomalies in the primary dentition of Belgian children.

5.

Malocclusion, dental injuries and dental anomalies in the primary dentition of Belgian children.

6.

Malocclusion, dental injuries and dental anomalies in the primary dentition of Belgian children.

7.

Malocclusion, dental injuries and dental anomalies in the primary dentition of Belgian children.

8.

Malocclusion, dental injuries and dental anomalies in the primary dentition of Belgian children.

1.

Comparison of the Belgian Rheumatoid Arthritis Disability Assessment and Health Assessment Questionnaires as Tools to Predict the Need for Support Measures in Patients with Rheumat...

2.

Comparison of the Belgian Rheumatoid Arthritis Disability Assessment and Health Assessment Questionnaires as Tools to Predict the Need for Support Measures in Patients with Rheumat...

3.

Comparison of the Belgian Rheumatoid Arthritis Disability Assessment and Health Assessment Questionnaires as Tools to Predict the Need for Support Measures in Patients with Rheumat...

4.

Comparison of the Belgian Rheumatoid Arthritis Disability Assessment and Health Assessment Questionnaires as Tools to Predict the Need for Support Measures in Patients with Rheumat...

5.

Comparison of the Belgian Rheumatoid Arthritis Disability Assessment and Health Assessment Questionnaires as Tools to Predict the Need for Support Measures in Patients with Rheumat...

6.

Comparison of the Belgian Rheumatoid Arthritis Disability Assessment and Health Assessment Questionnaires as Tools to Predict the Need for Support Measures in Patients with Rheumat...

7.

Comparison of the Belgian Rheumatoid Arthritis Disability Assessment and Health Assessment Questionnaires as Tools to Predict the Need for Support Measures in Patients with Rheumat...

8.

Comparison of the Belgian Rheumatoid Arthritis Disability Assessment and Health Assessment Questionnaires as Tools to Predict the Need for Support Measures in Patients with Rheumat...

1.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

2.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

3.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

4.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

5.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

6.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

7.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

8.

Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

1.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

2.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

3.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

4.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

5.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

6.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

7.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

8.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

1.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

2.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

3.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

4.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

5.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

6.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

7.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

8.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

1.

A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.

2.

A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.

3.

A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.

4.

A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.

5.

A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.

6.

A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.

7.

A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.

8.

A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme.

1.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

2.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

3.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

4.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

5.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

6.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

7.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

8.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.